Prelude Therapeutics Inc
| Fiscal year | Operating cash flow | Stock comp | Capex | Free cash flow | Net borrowing | FCFE | Shares (B) | FCF per share | Year-end price | FCF yield |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -0.1 | 0.0 | 0.0 | -0.1 | 0.0 | -0.1 | 0.05 | $-2.24 | $12.45 | -18.0% |
| 2022 | -0.1 | 0.0 | 0.0 | -0.1 | 0.0 | -0.1 | 0.05 | $-2.36 | $6.04 | -39.1% |
| 2023 | -0.1 | 0.0 | 0.0 | -0.1 | 0.0 | -0.1 | 0.06 | $-2.26 | $4.27 | -52.8% |
| 2024 | -0.1 | 0.0 | 0.0 | -0.1 | 0.0 | -0.1 | 0.08 | $-1.65 | $1.28 | -129.3% |
| 2025 | -0.1 | 0.0 | 0.0 | -0.1 | 0.0 | -0.1 | 0.08 | $-0.89 | $2.90 | -30.6% |
| 4-yr CAGR | n/m | -13.1% | -58.8% | n/m | n/a | n/m | 12.8% | n/m | -30.5% | avg -54.0% |
| Fiscal year | Revenue | EBITDA | EBITDA margin | Debt incl. leases | Cash & securities | Market cap | Enterprise value | EV / EBITDA | Net debt / EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| 2021 | 0.0 | -0.1 | n/m | 0.0 | 0.3 | 1 | 0 | n/m | n/m |
| 2022 | 0.0 | -0.1 | n/m | 0.0 | 0.2 | 0 | 0 | n/m | n/m |
| 2023 | 0.0 | -0.1 | n/m | 0.0 | 0.2 | 0 | 0 | n/m | n/m |
| 2024 | 0.0 | -0.1 | -1,970.6% | 0.0 | 0.1 | 0 | -0 | n/m | n/m |
| 2025 | 0.0 | -0.1 | -850.3% | 0.0 | 0.1 | 0 | 0 | n/m | n/m |
| 4-yr CAGR | n/m | n/m | avg -1,410.4% | 78.8% | -22.8% | -21.7% | -17.9% | median n/m | avg n/m |
Revenue grew n/m a year and EBITDA n/m a year from FY2021 to FY2025, and free cash flow after stock compensation did not grow from a positive base. The share count rose 12.8% a year, so per-share figures grew more slowly than the totals. The balance sheet carried more cash than debt in every one of those years.
From the data: EBITDA was not positive in enough years to set a growth rate and an exit multiple, so there is no hurdle price. The share count moved 27% in FY2023 with no split on record (a merger, offering or buyback), so per-share figures before and after that year are not on one basis. The share count moved 26% in FY2024 with no split on record (a merger, offering or buyback), so per-share figures before and after that year are not on one basis.
- Free cash flow is operating cash flow less stock-based compensation less capital spending. Stock comp is treated as a real cost.
- Net borrowing is the year's change in long-term debt. FCFE adds it back to free cash flow, the classic one-page definition.
- EBITDA is operating income plus depreciation and amortization. Debt includes lease obligations; cash includes short-term investments.
- Market cap uses the fiscal year-end price as traded, restated for later splits but not for dividends; enterprise value adds debt and subtracts cash.
- Share count is the yearly change in shares outstanding over the period; flat or falling clears. Cash margin is the latest free cash flow margin against its three-year average; within two points clears.
- Hurdle price is the present value, at the hurdle rate, of ten years of modeled free cash flow per share plus a year-10 sale at the exit multiple. It is shown as an exhibit: the 2011 to 2021 back-test found that buying below it did not sort winners from losers, so it is not scored.
- Cleared on a check means the number clears the stated rule; Not cleared means it does not. Durable, Holding and First year say how many fiscal years running the company has cleared all four staying-power checks (four or more, two or three, one); Partial and Not cleared count the checks it clears today. All of it is fact about the filings, not a rating of the stock.